期刊文献+

SKM-1细胞地西他滨耐药机制中hENT1功能的研究 被引量:1

Functional study of hENT1 on SKM-1 cell resistance to decitabine
原文传递
导出
摘要 目的 观察干扰1型平衡核苷转运体(human equilibrative nucleoside transporters 1,hENT1)表达后,地西他滨(DAC)对人骨髓增生异常综合征(MDS)细胞系SKM-1细胞的增殖、凋亡和去甲基化的影响.方法 采用慢病毒干扰技术沉默SKM-1细胞中hENT1,采用RT-PCR方法检测靶细胞内hENT1 mRNA表达水平,采用CCK-8法检测不同浓度DAC(0.5、1、5 μmol/L)作用24、48及72 h对hENT1沉默SKM-1细胞的增殖抑制情况,应用流式细胞术及Western blot法观察DAC诱导的凋亡情况,采用甲基化特异性PCR检测p15^INK4B去甲基化水平,分析hENT1沉默后DAC的去甲基化作用.结果 hENT1干扰组hENT1 mRNA表达水平(0.253±0.030)相对于对照组(1.000±0.091)显著降低(P<0.01);经0.5、1、5μmol/L DAC作用24、48及72 h后,相对于同时期对照组,hENT1干扰组的增殖抑制率均明显下降(P<0.05),其中5 μmol/L DAC作用72 h最为明显,hENT1干扰组和对照组分别为(49.41±4.02)%和(33.03±2.47)%(P=0.007);hENT1干扰组Caspase-3的剪切体水平及Annexin Ⅴ+细胞比例减少,并且p15^INK4B去甲基化水平也显著降低.结论 hENT1沉默后SKM-1细胞对DAC诱导的凋亡及去甲基化作用敏感性下降. Objective To investigate the effect of human equilibrative nucleoside transporters 1 (hENT1) silencing on proliferation,apoptosis and demethylation of human myelodysplastic syndrome (MDS) derived cell line SKM-1 treated with 5-aza-2'-deoxycytidine (decitabine,DAC).Methods hENT1 was silenced in SKM-1 cells mediated by lentivirus transfection.The infection efficiency was detected by flow cytometry,and the mRNA expression level of hENT 1 was confirmed by qRT-PCR.The proliferation ratio of SKM-1 cells treated with different concentrations (0.5,1,5 mmol/L) of DAC for 24,48 and 72h was detected by CCK-8 method after hENT1 silencing.The apoptosis of SKM-1 cells was detected by Western blot for cleaved level of caspase-3 and evaluated by flow cytometry after staining with anti-Annexin Ⅴ-PE and 7-AAD.The p15^INK4B DNA methylation status was measured by methylation specific PCR using EZ DNA Methylation-Gold^TM Kit.Results The expression level of hENT1 silenced group (0.253±0.030) was statistically decreased compared with that in control group (1.000±0.091) (P〈0.01).Compared with control,the proliferation inhibition rate of hENT1 silenced group was significantly decreased by different concentrations of DAC (0.5,1,5 μmol/L) treatment for 24,48,72 h (P〈0.05),which was (49.41±4.02)% and (33.03±2.47)%,respectively (P=0.007) at 5 μmol/L DAC treatment for 72 h in hENT1 silenced group and the control group.Western blot showed that cleaved caspase3 of hENT1 silenced group was also significantly inhibited.The percentage of Annexin Ⅴ + cells and demethylation status of p15^INK4B were significantly decreased.Conclusion Apoptosis of hENT1 silenced SKM-1 cells induced by DAC was decreased,and the susceptibility of these cells to demethylation treatment was also decreased.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2015年第5期408-412,共5页 Chinese Journal of Hematology
关键词 平衡核苷转移子1 地西他滨 SKM-1细胞 抗药性 Equilibrative nucleoside transporter 1 Decitabine SKM-1 cells Drug resistance
  • 相关文献

参考文献20

  • 1Nimer SD. Myelodysplastic syndromes [J]. Blood, 2008, 111 (10): 4841-4851.
  • 2Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase Ill randomized study IJ]. Cancer, 2006, 106 (8): 1794- 1803.
  • 3Kong W, Engel K, Wang J. Mammalian nucleoside transporters [J]. Curr Drug Metab, 2004, 5( 1): 63-84.
  • 4Young JD, Yao SY, Baldwin JM, et al. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29I J. Mol Aspects Med, 2013, 34(2-3): 529-547.
  • 5Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment [J]. Lancet Oncol, 2002, 3 (7): 415-424.
  • 6Hummel-Eisenbeiss J, Hascher A, Hals PA, et al. The role of human equilibrative nucleoside transporter I on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells [J]. Mol Pharmacol, 2013, 84(3): 438-450.
  • 7Galmarini CM, Thomas X, Calvo F, et al. Potential mechanisms of resistance to eytarahine in AML patients J 1. Leuk Res, 2002, 26(7): 621-629.
  • 8Zimmerman El, Huang M, Leisewitz AV, et al. Identification of a novel point mutation in ENT 1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells [J]. FEBS Lett, 2009, 583(2): 425-429.
  • 9Mardchal R, Bachet JB, Mackey JR, et aL Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma [J]. Gastroenterology, 2012, 143(3): 664-674. el-6.
  • 10Borbath I, Verbmgghe L, Lai R, et al. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma [ J ]. Eur J Cancer, 2012, 48 ( 7 ): 990-996.

二级参考文献13

  • 1Reynisdottir I, Massague J. The subcellular locations of p15 (Ink4b) and p27 ( Kipl ) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev, 1997, 11:492-503.
  • 2Ng MH, Chung YF, Lo KW, et al. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood,1997, 89: 2500- 2506.
  • 3Hofmann WK, Koeffler HP. Important features of myelodysplastic syndrome. Int J Hematol, 2002, 76: 222-227.
  • 4Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase Ⅲ randomized study. Cancer, 2006, 106:1794-1803.
  • 5Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a ran- domized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 2007,109:52-57.
  • 6Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neo-plasms and acute leukemia: rationale and important changes. Blood, 2009, 114 : 937-951.
  • 7Herman JG, Graft JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A, 1996, 93: 9821-9826.
  • 8Aoki E, Uchida T, Ohashi H, et al. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia, 2000, 14 : 586- 593.
  • 9Aggerholm A, Holm MS, Guldberg P, et al. Promoter byperm- ethylation of p15INK4B, HIC1, CDH1, and ER is frequent in my- elodysplastie syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol, 2006, 76: 23-32.
  • 10Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplas- tic syndrome by 5-Aza-2' -deoxycytidine (decitabine) treatment. Blood, 2002,100:2957-2964.

共引文献79

同被引文献7

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部